Ken Griffin Seagen Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $43.7 Million - $49.3 Million	-228,000 Reduced 67.16%	111,500 $23.7 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $56.2 Million - $61.7 Million	299,300 Added 744.53%	339,500 $65.3 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $4.66 Million - $7.41 Million	-36,500 Reduced 47.59%	40,200 $8.14 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $5.86 Million - $6.94 Million	49,900 Added 186.19%	76,700 $9.86 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $21.3 Million - $28.4 Million	-157,600 Reduced 85.47%	26,800 $3.67 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.